Novel antibody targets fat cell protein, offering new approach to treating metabolism-related liver cancerNovel antibody targets fat cell protein, offering new approach to treating metabolism-related liver cancer
Liver cancer is one of the three deadliest cancers worldwide, and metabolic dysfunction-related cases have become increasingly common in recent years. A research team from The Hong Kong Polytechnic University (PolyU) has identified a protein secreted by fat cells that promotes cancer growth and has successfully developed a novel antibody that neutralizes this protein, marking a significant breakthrough in impeding the progression of liver cancer. The research findings have been published in the Journal of Clinical Investigation.
STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competitionSTAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market. The Danish pharma giant said it expects sales to decrease in the range of 5% to 13% in 2026, more than the 3% decrease forecasted by analysts surveyed by Read More
NIH Grant Disruptions Slow Down Breast Cancer ResearchNIH Grant Disruptions Slow Down Breast Cancer Research
(MedPage Today) — Inside a cancer research laboratory on the campus of Harvard Medical School, two dozen small jars with pink plastic lids sat on a metal counter. Inside these humble-looking jars is the core of the current multiyear research project…
GLP-1 drugs tied to lower-calorie, lower-sugar food purchasesGLP-1 drugs tied to lower-calorie, lower-sugar food purchases
Researchers at Steno Diabetes Center Copenhagen reported that starting a GLP-1 receptor agonist (GLP-1RA) coincided with slightly healthier supermarket purchases. Grocery purchases from GLP-1RA users in Denmark contained modestly fewer calories and sugars and slightly more protein per 100 g of food after treatment began than before. Researchers at Steno Diabetes Center Copenhagen reported that Read More
NIH Grant Disruptions Slow Down Breast Cancer ResearchNIH Grant Disruptions Slow Down Breast Cancer Research
The Trump administration has made the future of federal funding for cancer research uncertain. At one groundbreaking breast cancer research lab, work that could save lives has slowed significantly.
Addition of palbociclib improves progression-free survival in HR-positive, HER2-positive metastatic breast cancerAddition of palbociclib improves progression-free survival in HR-positive, HER2-positive metastatic breast cancer
For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine therapies leads to improved progression-free survival, according to a study published in the Jan. 29 issue of the New England Journal of Medicine.
GLP-1 Drugs May Protect Against Vertebral FracturesGLP-1 Drugs May Protect Against Vertebral Fractures
Glucagon-like peptide-1 (GLP-1) receptor agonists were associated with a lower vertebral fracture risk in patients with type 2 diabetes, according to a study published in JAMA Surgery. Glucagon-like peptide-1 (GLP-1) receptor agonists were associated with a lower vertebral fracture risk in patients with type 2 diabetes, according to a study published in JAMA Surgery.
WHO Guideline on GLP-1 Therapies for Obesity in AdultsWHO Guideline on GLP-1 Therapies for Obesity in Adults
This Special Communication summarizes the WHO guideline on the management of obesity with GLP-1 therapies in adults and calls on nations to ensure equitable access to obesity prevention and management interventions. This Special Communication summarizes the WHO guideline on the management of obesity with GLP-1 therapies in adults and calls on nations to ensure equitable Read More
GLP-1 Pill Cut Heart Failure Events in Some Diabetes PatientsGLP-1 Pill Cut Heart Failure Events in Some Diabetes Patients
(MedPage Today) — Oral semaglutide (Rybelsus) protected against heart failure events in type 2 diabetes patients with a history of heart failure and either atherosclerotic cardiovascular disease, chronic kidney disease, or both, according to findings… (MedPage Today) — Oral semaglutide (Rybelsus) protected against heart failure events in type 2 diabetes patients with a history Read More
New genetic tools offer more accurate breast cancer prediction for women of African ancestryNew genetic tools offer more accurate breast cancer prediction for women of African ancestry
Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among women of African ancestry. This is often due to a combination of factors, including failure of existing genetic models to accurately predict risk, higher rates of aggressive tumor subtypes, and later-stage diagnoses.